Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG
- 11 October 2019
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (3) , e494-e501
Abstract
Context Prognosis of metastatic pheochromocytoma/paraganglioma following 131-Iodine metaiodobenzylguanidine (MIBG) is incompletely characterized due to small samples and shorter follow-up in these rare, often indolent tumors. Objective To describe long-term survival, frequency, and prognostic impact of imaging, biochemical, and symptomatic response to 131-I MIBG. Design Retrospective chart and imaging review at a tertiary referral center. Patients Six hundred sixty-eight person-years of follow-up in 125 patients with metastatic pheochromocytoma/paraganglioma with progression through prior multimodal treatment. Intervention Median 18 800 MBq 131-I MIBG. Main Outcome Measures Overall survival, Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST) imaging response, symptomatic response per chart review, and biochemical response (20% change over 2 consecutive assays of catecholamines, vanillylmandelic acid, metanephrines, or chromogranin A). Results Median survival standard deviation [SD] from diagnosis was 11.5 years [2.4]; following metastasis, 6.5 years [0.8]; post treatment, 4.3 years [0.7]. Among 88 participants with follow-up imaging, 1% experienced complete response, 33% partial response, 53% stability, and 13% progression. Fifty-one percent showed subsequent progression, median progression-free survival [SD] of 2.0 years [0.6]. Stability/response vs progression at first imaging follow-up (3–6 months) predicted improved survival, 6.3 vs 2.4 years (P = 0.021). Fifty-nine percent of 54 patients demonstrated biochemical response. Fifty percent of these relapsed, with median time to laboratory progression [SD] of 2.8 years [0.7]. Biochemical response did not predict extended survival. Seventy-five percent of 83 patients reported improvement in pretreatment symptoms, consisting primarily of pain (42%), fatigue (27%), and hypertension (14%). Sixty-one percent of these patients experienced subsequent symptomatic progression at median [SD] 1.8 years [0.4]. Symptomatic response did not predict extended survival. Conclusions Imaging, symptomatic, and laboratory response to multimodal treatment including high-dose 131-I MIBG were achieved on long-term follow-up in metastatic pheochromocytoma or paraganglioma. Imaging response at 3 to 6 months was prognostic.Keywords
Funding Information
- Duke School of Medicine
- NIH
This publication has 21 references indexed in Scilit:
- I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and ParagangliomaSeminars in Nuclear Medicine, 2016
- Metastatic pheochromocytoma and paragangliomaEuropean Journal of Clinical Investigation, 2015
- The Social Security Death Index (SSDI) most accurately reflects true survival for older oncology patients.2013
- Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic ParagangliomaCurrent Oncology Reports, 2013
- An Overview of Practical Approaches for Handling Missing Data in Clinical TrialsJournal of Biopharmaceutical Statistics, 2009
- Radiation Dosimetry, Pharmacokinetics, and Safety of Ultratrace™ Iobenguane I-131 in Patients with Malignant Pheochromocytoma/Paraganglioma or Metastatic CarcinoidCancer Biotherapy and Radiopharmaceuticals, 2009
- Validation of the Social Security Death Index (SSDI): An Important Readily-Available Outcomes Database for Researchers2008
- Overview of Missing Data Techniques2007
- Year of Diagnosis, Features at Presentation, and Risk of Recurrence in Patients with Pheochromocytoma or Secreting ParagangliomaThe Journal of Clinical Endocrinology & Metabolism, 2005
- Pheochromocytomas: can malignant potential be predicted?Urology, 1999